<DOC>
	<DOCNO>NCT00839384</DOCNO>
	<brief_summary>The purpose Advisa IPG clinical study evaluate overall system safety clinical performance Advisa DR Implantable Pulse Generator ( IPG ) .</brief_summary>
	<brief_title>AdvisaTM IPG Clinical Evaluation Study</brief_title>
	<detailed_description>The Advisa IPG investigational dual chamber pacemaker provide rate-responsive bradycardia pace diagnostics atrial tachycardia detection therapy . The study prospective , non-randomized , multicenter clinical study , conduct . To allow sufficient experience device , maximum 80 subject may implant Advisa device . Data collect baseline ( enrollment ) , implant , 1- , 3- 6- month post implant every 6 month thereafter study closure ( whichever occurs first ) , unscheduled follow-up visit , System Modifications , Technical Observations , Study Deviations , Study Exit , upon notification new updated Adverse Events case death .</detailed_description>
	<mesh_term>Bradycardia</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<criteria>Patients IPG indication implantation dual chamber pacemaker . Patients geographically stable available followup study center duration study . Patients sign Medical Ethics Committee ( MEC ) approve Informed Consent form . Patients life expectancy less duration study . Patients Class III indication permanent pace accord ACC/AHA/NASPE 2002 guideline . Patients medical condition preclude test require patient study protocol otherwise limit study participation require patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>